On July 15, 2026, Neko Health, the body-scanning startup founded by Spotify's Daniel Ek and Hjalmar Nilsonne, announced a $700 million Series C that values the company at close to $7 billion, roughly four times its mark from eighteen months earlier. The round funds a push into the United States, starting with a flagship clinic in Manhattan. It is one of the year's largest health-tech raises, and it is a clean case study in a specific bet: that AI-driven scanning can shift medicine from reacting to disease toward catching it early. This piece looks at what Neko actually does, why the vertically integrated model is unusual, and the questions the funding does not answer.
What Neko actually does
Neko Health operates physical clinics where a member undergoes a full-body scan combined with bloodwork. Its own imaging hardware captures a large volume of data about skin, cardiovascular markers, and other physiological signals, and software, including AI models, analyzes that data to flag anything that may warrant follow-up. The pitch is a fast, non-invasive, data-rich health assessment that establishes a baseline and, over repeat visits, tracks change over time.
The strategic choice that sets Neko apart is vertical integration. Rather than selling software into existing clinics or partnering with hardware makers, Neko engineers its own scanning hardware, builds its own clinical software, and runs its own clinic footprint. It owns the full stack, from the sensor to the exam room. That is capital-intensive and slow to scale, which is a large part of why a $700 million round is needed to expand into one new country, but it also means the company controls the entire experience and, crucially, the entire data pipeline that its AI depends on.
A fourfold mark in eighteen months
Neko Health's reported valuation, in billions of dollars, across its last two rounds. The re-rating comes largely ahead of, rather than after, a large-scale US clinical footprint.
The $700M Series C values Neko at close to $7 billion, roughly four times its $1.7 billion Series B mark from January 2025.
The preventive-medicine thesis
The idea underneath the company is older than any AI model: most healthcare systems are built to treat disease once it presents, and detecting problems earlier should improve outcomes and reduce downstream cost. Preventive medicine is not new. What is new is the claim that high-resolution scanning plus AI analysis can make broad, regular screening practical and informative at a scale and price that traditional diagnostics have not reached.
The compelling version is early detection at population scale. The unresolved version is whether scanning healthy people produces more early saves or more false alarms.
This is where a neutral account has to be careful, because the thesis has a genuinely compelling version and a genuinely unresolved version, and they sit close together. The compelling version is that catching a serious condition early, when it is cheaper and more treatable, is obviously valuable, and that richer data plus better pattern recognition should help. The unresolved version is the long-running debate in medicine about screening asymptomatic people: broad screening can surface real problems early, and it can also generate false positives and incidental findings that lead to anxiety, further tests, and interventions that may not improve outcomes. AI changes the resolution and the cost of the scan; it does not by itself settle whether screening a given population produces net benefit. That question is answered by clinical evidence over time, not by a funding round.
Why the valuation moved before the evidence did
A near-$7 billion valuation, up fourfold from the $1.7 billion Series B in January 2025, is a striking re-rating for a company that is only now entering its largest target market. Two things explain the investor enthusiasm, and both are worth stating plainly.
The first is the profile of the round. It was led by Lightspeed Venture Partners and O.G. Venture Partners, and the participant list included Mark Zuckerberg and Priscilla Chan, Tim Ferriss, will.i.am, and OpenAI, among others. That mix of technology and high-profile backers signals conviction and buys attention, and it also reflects how much capital is currently seeking exposure to AI applied to large, non-software markets such as healthcare.
The second is the size of the prize. If regular preventive scanning becomes a normal part of how people manage their health, the addressable market is enormous, and a vertically integrated operator that owns the hardware, the clinics and the data could hold a durable position. The valuation is priced against that possibility. The honest framing is that investors are underwriting a large potential outcome that depends on clinical results, consumer behavior and health-system economics that are not yet proven at scale. That is a normal venture bet; it is simply important not to mistake a high valuation for validated medical benefit.
The data question, and why it cuts both ways
Neko's most interesting long-term asset may be its data. A vertically integrated operator running standardized scans across a growing member base accumulates a large, consistent dataset of longitudinal health measurements. In principle, that data improves the AI models over time, and better models improve the value of the scan, a flywheel that a fragmented set of clinics using off-the-shelf software could not easily build.
That same concentration raises the stakes on governance. Highly sensitive medical and biometric data, held by a single private company, demands rigorous privacy protection, security, and clear limits on use, and it invites regulatory attention that varies sharply by jurisdiction, which is one reason a US expansion is a meaningful step change rather than a simple copy-paste of the European operation. The data flywheel is a real potential advantage and a real responsibility at the same time, and how Neko handles the second will shape how much it is trusted to build the first.
What it means more broadly
For anyone watching where AI is being applied, Neko is a useful example of a larger pattern in 2026: some of the biggest bets are no longer on the models themselves but on applying AI inside capital-intensive, regulated, physical industries, healthcare, manufacturing, energy, where the value is large and the execution is hard. These are not pure-software plays. They require hardware, physical operations, regulatory navigation and, above all, evidence, and they scale more slowly and expensively than an app.
The through-line with the rest of the AI economy is that the model is rarely the whole product. Neko's advantage, if it materializes, will come from the integrated system, the hardware, the clinics, the longitudinal data and the workflow, with the AI as one component matched to the task rather than the entire proposition. That is the same lesson visible across applied AI: the durable value tends to sit in how intelligence is integrated into a real workflow, not in access to a model alone. It is the reasoning behind flexible, model-agnostic tools such as Metir AI in the software domain, and it holds, in a far more capital-intensive form, in the physical one.
The bigger picture
Neko Health's $700 million round is a large, high-profile wager on a genuinely important idea, that AI-enabled scanning can move medicine toward earlier detection, executed through an unusually integrated and capital-heavy model. The ambition is real and so is the caliber of the backing.
What the funding does not resolve is the question that ultimately decides whether the bet pays off: whether broad preventive scanning of largely healthy people produces net clinical benefit, and whether it does so at a cost and consumer experience that make it a routine part of healthcare. That answer will come from clinical evidence and real-world results over years, not from a valuation. The raise buys Neko the runway to try to produce it, which is the appropriate way to read the news, as the funding of an ambitious experiment rather than the proof of its conclusion.
Sources:
- Daniel Ek's body-scanning startup Neko Health raises another $700M | TechCrunch
- Daniel Ek's Neko Health Secures $700M to Fund U.S. Preventive Clinic Expansion | HIT Consultant
- Neko Health Raises $700M Series C at Nearly $7B Valuation for U.S. Expansion | MLQ News
- Neko Health raises $700m Series C ahead of US launch | Neko Health